| Identification | Back Directory | [Name]
BIBB 515 | [CAS]
156635-05-1 | [Synonyms]
BIBB 515
Methanone, (4-chlorophenyl)[4-[[4-(4,5-dihydro-2-oxazolyl)phenyl]methylene]-1-piperidinyl]-
(4-chlorophenyl)-[4-[[4-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methylidene]piperidin-1-yl]methanone | [Molecular Formula]
C22H21ClN2O2 | [MDL Number]
MFCD00930515 | [MOL File]
156635-05-1.mol | [Molecular Weight]
380.87 |
| Chemical Properties | Back Directory | [Boiling point ]
586.5±50.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:1.38(Max Conc. mg/mL);3.62(Max Conc. mM)
DMF:0.3(Max Conc. mg/mL);0.79(Max Conc. mM)
Ethanol:0.15(Max Conc. mg/mL);0.39(Max Conc. mM) | [form ]
White solid. | [pka]
4.72±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL)[1]. | [in vivo]
BIBB 515 (16.0-148.2 mg/ kg; oral administration; daily; for 40 days; male golden Syrian hyperlipemic hamsters) treatment shows dose-dependent lipid-lowering activity in normolipemic hamsters (-19% for total cholesterol and -32% for VLDL + LDL cholesterol) and in hyperlipemic hamsters (-25% for total cholesterol and -59% for LDL-cholesterol)[1]. | Animal Model: | Male golden Syrian hyperlipemic hamsters (~100 g)[1] | | Dosage: | 16.0 mg/ kg, 49.7 mg/ kg, and 148.2 mg/ kg | | Administration: | Oral administration; daily; for 40 days | | Result: | Dose-dependent lipid-lowering activity was seen in normolipemic hamsters after 11 days treatment (-19% for total cholesterol and -32% for VLDL + LDL cholesterol at 55 mg/kg/day) and in hyperlipemic hamsters after 25 days (-25% for total cholesterol and -59% for LDL-cholesterol at 148 mg/kg/day).
|
| [References]
[1] Eisele B, et al. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75. PMID:9101437 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
|